PHIO_OUT_1 [2025-04-16 13:38:18 -0400] 4258 Bytes | 1071 tokens | Cum: 1071 tkns (13.39% of 8k)
==========================================================================

Listen up, partner—it's 1:38:17 PM on Wed Apr 16, 2025 -0400, and I’m revved up about Phio Pharmaceuticals (PHIO), climbing from 2.4300 to 2.8700. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Phio Pharmaceuticals (PHIO)
IPO: 2012-05-10 (12 Years Ago)
Market Cap: $7,358,357
Shares Outstanding: 4,780,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Here’s a list of headlines for Phio Pharmaceuticals:

Apr-10-25 10:53AM - PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
Apr-09-25 07:45AM - Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Apr-03-25 07:45AM - Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
Mar-31-25 04:00PM - Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
Mar-10-25 07:45AM - American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Mar-05-25 07:45AM - Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
Feb-26-25 07:45AM - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Feb-20-25 07:45AM - Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-08-23T15:47:00Z - Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033
B2 - 2024-05-17T13:00:00Z - Phio Pharmaceuticals Secures New Investor
B3 - 2024-05-15T17:00:00Z - Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
B4 - 2024-05-09T21:25:00Z - Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
B5 - 2024-04-30T11:30:00Z - Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
B6 - 2024-04-22T17:10:00Z - Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Phio Pharmaceuticals (PHIO).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

PHIO_OUT_3 [2025-04-16 13:38:18 -0400] 682 Bytes | 204 tokens | Cum: 1277 tkns (15.96% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/15/2882744/0/en/Phio-Pharmaceuticals-Announces-Completion-of-Dosing-in-First-Patient-Cohort-in-PH-762-Phase-1b-Dose-Escalation-Study.html-PH-762 is Phio’s lead product candidate

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_5 [2025-04-16 13:38:19 -0400] 963 Bytes | 294 tokens | Cum: 1573 tkns (19.66% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-09T21:36:00Z - DelveInsight Business Research, LLP: Merkel Cell Carcinoma Market to Grow Rapidly at a CAGR of 8.7% ...
A2 - 2025-04-09T18:50:15Z - Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retai...
A3 - 2025-04-09T16:43:22Z - Wall Street-Heavily Traded...
A4 - 2025-04-09T16:06:32Z - Crude Oil Down 4%; Neogen Shares Plunge After Q3 Results - Bloom Energy (NYSE:BE), Neogen (NASDAQ:NE...
A5 - 2025-04-09T14:39:15Z - Phio Pharma Stock Up 115% On Safety Clearance To Advance With Dose Escalation In Skin Cancer Study...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PHIO_OUT_7 [2025-04-16 13:38:20 -0400] 1182 Bytes | 355 tokens | Cum: 1930 tkns (24.12% of 8k)
==========================================================================

Showing A1 (chunk 1 of 20): A1:
**DelveInsight Business Research, LLP: Merkel Cell Carcinoma Market to Grow Rapidly at a CAGR of 8.7% During the Study Period (2020-2034) | DelveInsight**Date: 2025-04-09Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-04/65075350-delveinsight-business-research-llp-merkel-cell-carcinoma-market-to-grow-rapidly-at-a-cagr-of-8-7-during-the-study-period-2020-2034-delveinsight-008.htmThe Merkel cell carcinoma market is poised for steady growth, with a strong CAGR projected from 2024 to 2034. This expansion across the 7MM will be driven by the launch of innovative therapies, including IFx-2.0, NIDLEGY, and ITI-3000.

LAS VEGAS, April 9, 2025 /PRNewswire/ -- DelveInsight's Merkel Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, Merkel

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_9 [2025-04-16 13:38:21 -0400] 1182 Bytes | 295 tokens | Cum: 2227 tkns (27.84% of 8k)
==========================================================================

Showing A1 (chunk 2 of 20): cell carcinoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Merkel Cell Carcinoma Market Report

According to DelveInsight's analysis, the market size for Merkel cell carcinoma was found to be USD 411 million in the 7MM in 2023.According to estimates, among the currently marketed drugs, BAVENCIO (avelumab) as first-line therapy held the largest market share, generating approximately USD 290 million in revenue across the 7MM in 2023.According to DelveInsight's estimates, in 2023, there were approximately 9K incident cases of MCC in the 7MM. Of these, the United States accounted for 37% of the cases.Leading Merkel cell carcinoma companies developing emerging therapies, such as TuHURA

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_11 [2025-04-16 13:38:21 -0400] 1182 Bytes | 291 tokens | Cum: 2520 tkns (31.50% of 8k)
==========================================================================

Showing A1 (chunk 3 of 20): Biosciences, Philogen, Immunomic Therapeutics, Phio Pharmaceuticals, AgonOx, Kymera Therapeutics, Merus N.V., and others are developing novel Merkel cell carcinoma drugs that can be available in the Merkel cell carcinoma market in the coming years. The promising Merkel cell carcinoma therapies in the pipeline include IFx-2.0, NIDLEGY (L19-IL2/L19-TNF), ITI 3000, PH 762, KT 253, MCLA 145, and others.

Discover which therapies are expected to grab the major Merkel cell carcinoma market share @ Merkel Cell Carcinoma Market Report

Merkel Cell Carcinoma Overview

Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that originates from Merkel cells, which are neuroendocrine cells involved in touch sensation. While its exact causes are not completely understood, several risk factors have been identified, including prolonged exposure to ultraviolet (UV) radiation, advanced age, an

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_13 [2025-04-16 13:38:22 -0400] 1182 Bytes | 263 tokens | Cum: 2785 tkns (34.81% of 8k)
==========================================================================

Showing A1 (chunk 4 of 20): d a weakened immune system; additionally, infection with the Merkel Cell Polyomavirus (MCPyV) is associated with many cases of MCC.

Clinically, MCC often presents as a rapidly growing, firm, and painless nodule that may appear red, violet, or flesh-colored, typically on sun-exposed areas such as the head, neck, or extremities. Diagnosis usually begins with a detailed physical examination and imaging studies to assess the extent of the lesion, but a definitive diagnosis is made through a biopsy followed by histopathological and immunohistochemical analyses, which help distinguish MCC from other similar skin tumors.

Merkel Cell Carcinoma Epidemiology Segmentation

The Merkel cell carcinoma epidemiology section provides insights into the historical and current Merkel cell carcinoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted pati

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_15 [2025-04-16 13:38:22 -0400] 1083 Bytes | 280 tokens | Cum: 3067 tkns (38.34% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER ##TABLE_END

The following discussion of our financial condition and results of operations should be read in conjunction with our CONS financial statements and the notes to thos...

S2 - 2025-03-31 8-K Item 2.02. Results of Oper and Fin Cond.

On March 31, 2025, Phio Pharmaceuticals Corp. (the Company) reported its financial results for the quarter and year ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 to this Curre...

S4 - 2025-01-17 8-K Item1.01. Entry into a Material Definitive Agrmt.

Concurrent Registered Direct Offering and Private Placement

On January 16, 2025, Phio Pharmaceuticals Corp. (the Company) entered into a securities purchase agreement (the Securities Purchase Agrmt) with certain instit...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PHIO_OUT_17 [2025-04-16 13:38:23 -0400] 1181 Bytes | 254 tokens | Cum: 3323 tkns (41.54% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ##TABLE_END

The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the notes to those consolidated financial statements included in Item 8 of this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth under Risk Factors and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated in these forward-looking statements. Please refer to the discussion under the heading Forward-Looking Statements above.

Overview

Phio Pharmaceuticals Corp. ( Phio , we , our or the Company ) is a clinical stage biotechnology company w

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_19 [2025-04-16 13:38:24 -0400] 1181 Bytes | 261 tokens | Cum: 3586 tkns (44.82% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): hose proprietary INTASYL self-delivering RNAi small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the bodys ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future.

##TABLE_START 25 ##TABLE_END

PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 ( PD-1 ). PH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating clinical trial through the intratumoral injection of PH-762 for the treatment of patients with cutaneous squamous cell carcinoma, melanoma and Merkel ce

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_21 [2025-04-16 13:38:25 -0400] 1181 Bytes | 283 tokens | Cum: 3871 tkns (48.39% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ll carcinoma. The trial (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 and is expected to enroll up to 30 patients. In May and December 2024, respectively, a Safety Monitoring Committee (SMC) reviewed data from the first and second dose cohorts treated with PH-762, and in both instances recommended escalation to the next dose concentration. A total of 7 patients with cutaneous carcinomas have been enrolled in dose cohorts 1 and 2. The second cohort enrolled a total of 4 patients who were diagnosed with cutaneous squamous cell carcinoma. At Day 36 (tumor excision), while patients in the first cohort had stable disease, a complete response (100% tumor clearance) was reported for 2 patients with cutaneous squamous cell carcin

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_23 [2025-04-16 13:38:26 -0400] 1181 Bytes | 262 tokens | Cum: 4135 tkns (51.69% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): oma. Partial response (90% tumor clearance) was reported for 1 patient with cutaneous squamous cell carcinoma and 1 patient had stable disease, having not progressed. In this trial to date, intratumoral injection of PH-762 has been well tolerated in all enrolled patients and there were no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in the patients receiving intratumoral PH-762. The third dose cohort is fully enrolled and patients in this cohort are currently in the treatment or follow-up phase of the study. Phio expects to complete enrollment of all patients in the study in the third quarter of 2025.

In 2023, the Company implemented a cost rationalization program driven by its transition from discovery research to product development. This resulted in a decision not to renew the lease for office and laboratory space in Marlborough, Massachusetts, w

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_25 [2025-04-16 13:38:28 -0400] 1181 Bytes | 274 tokens | Cum: 4411 tkns (55.14% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): hich expired on March 31, 2024. Beginning in April 2024, we have continued operations as a remote business with a laboratory facility in Worcester, Massachusetts. Beginning in January 2024, we rationalized discovery research personnel resulting in an overall headcount reduction by greater than 50%. Expense reductions have been redirected to funding the Phase 1b clinical trial with PH-762.

PH-762

PH-762 is an INTASYL compound designed to reduce the expression of PD-1. PD-1 is a protein that inhibits T cells ability to kill cancer cells and is a clinically validated target in immunotherapy. Decreasing the expression of PD-1 can thereby increase the capacity of T cells, which protect the body from cancer cells and infections, to kill cancer cells.

Our preclinical studies have demonstrated that direct-to-tumor application of PH-762 resulted in potent anti-tumoral effects and have shown t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_27 [2025-04-16 13:38:29 -0400] 790 Bytes | 181 tokens | Cum: 4594 tkns (57.43% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): hat direct-to-tumor treatment with PH-762 inhibits tumor growth in a dose dependent fashion in PD-1 responsive and refractory models. Importantly, direct-to-tumor administration of PH-762 resulted in activity against distant untreated tumors, indicative of a systemic anti-tumor response. We believe these data further support the potential for PH-762 to provide a strong local immune response without the dose immune-related adverse effects seen with systemic antibody therapy.

PH-762 is currently bein...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PHIO_OUT_29 [2025-04-16 13:38:36 -0400] 5810 Bytes | 1514 tokens | Cum: 6110 tkns (76.38% of 8k)
==========================================================================

This is our set of metrics for Phio Pharmaceuticals.
Please analyze the numbers.

+-------------------+----------------------+------------------------+-----------------------+
| Volume: 1,848,402 | Perf Month: 106.47% | Option/Short: No / No | Sales Y/Y TTM: - |
+-------------------+----------------------+------------------------+-----------------------+
| Avg Volume: 3.98M | Perf Quarter: 7.89% | Short Float: 1.86% | ROE: -114.83% |
+-------------------+----------------------+------------------------+-----------------------+
| Rel Volume: 0.75 | Index: - | Short Ratio: 0.02 | ROI: -151.39% |
+-------------------+----------------------+------------------------+-----------------------+
| RSI (14): 83.86 | Market Cap: 13.71M | Short Interest: 0.08M | Sales Surprise: - |
+-------------------+----------------------+------------------------+-----------------------+
| ATR (14): 0.32 | Shs Outstand: 4.78M | Beta: 0.69 | EPS Surprise: 125.20% |
+-------------------+----------------------+------------------------+-----------------------+
| SMA20: 94.08% | Shs Float: 4.23M | Sales Q/Q: - | P/E: - |
+-------------------+----------------------+------------------------+-----------------------+
| SMA50: 88.78% | Inst Own: 5.13% | Sales past 5Y: -20.00% | Earnings: Mar 31 AMC |
+-------------------+----------------------+------------------------+-----------------------+
| SMA200: 7.64% | Insider Own: 11.45% | Employees: 5 | |
+-------------------+----------------------+------------------------+-----------------------+
| Perf Week: 86.36% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+-------------------+----------------------+------------------------+-----------------------+

The next section covers any insider trading by Phio Pharmaceuticals officers or majority shareholders (if available).

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -7419000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.87
Average Volume: 7407252.7
30-Day High: 2.87
30-Day Low: 1.01

[Detailed Financials: Q3 2024]
- Total Assets: $5,865,000.0
- Total Liabilities: $919,000
- Total Equity: $4,946,000.0
- Current Assets: $5,864,000.0
- Current Liabilities: $919,000

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.54

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $5,296,000.0
- Total Liabilities: $-3,773,000.0
- Total Equity: $3,773,000.0
- Current Assets: $5,292,000.0
- Current Liabilities: $1,523,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3.62

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Phio Pharmaceuticals (PHIO).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Phio Pharmaceuticals.

2) MARKET_SCORE[]
This conversation was initiated because PHIO is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for PHIO.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, PHIO could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect PHIO to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Phio Pharmaceuticals.

11) ETHICAL_RATING[]
Rate Phio Pharmaceuticals’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Phio Pharmaceuticals.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

PHIO_IN_31 [2025-04-16 13:38:37 -0400] 126 Bytes | 29 tokens | Cum: 6359 tkns (79.49% of 8k)
==========================================================================

====================================
[2025-04-16 13:38:37] # Analysis Completed
Elapsed Time: 20.35 seconds